Entera Bio (ENTX) Change in Account Payables (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Change in Account Payables of -$174000.0 in Q1 2026, down 175.0% on a QoQ basis from $232000.0 in Q4 2025, and down 8800.0% year-over-year from $2000.0 in Q1 2025.
Entera Bio (ENTX) Change in Account Payables (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Change in Account Payables across 6 years of filings, most recently posting -$174000.0 for Q1 2026.
- Quarterly Change in Account Payables fell 8800.0% year-over-year to -$174000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140000.0 (up 105.88% YoY) and the FY2025 annual result came in at $316000.0, up 544.9% from the prior year.
- Change in Account Payables eased to -$174000.0 in Q1 2026, from $232000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $324000.0 in Q3 2023 and troughed at -$481000.0 in Q4 2023.
- A 5-year average of $6352.9 and a median of $3000.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2025 — Change in Account Payables surged 8200.0% — and 2026, when it sank 8800.0%.
- Tracing ENTX's Change in Account Payables over 5 years: stood at -$396000.0 in 2022, then decreased by 21.46% to -$481000.0 in 2023, then jumped by 89.19% to -$52000.0 in 2024, then soared by 546.15% to $232000.0 in 2025, then tumbled by 175.0% to -$174000.0 in 2026.
- Business Quant data shows ENTX's Change in Account Payables at -$174000.0 in Q1 2026, $232000.0 in Q4 2025, and -$167000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | -174,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -174,000.00 |
| Mar 31, 2026 | -174,000.00 |
| Dec 31, 2025 | 232,000.00 |
| Dec 31, 2025 | 232,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Jun 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 249,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Sep 30, 2024 | 115,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -17,000.00 |
| Mar 31, 2024 | -17,000.00 |
| Dec 31, 2023 | -481,000.00 |
| Dec 31, 2023 | -481,000.00 |